Division of Neurotology and Skull Base Surgery, Department of Otolaryngology-Head and Neck Surgery.
Department of Biomedical Engineering, University of California Irvine, Irvine, California.
Otol Neurotol. 2018 Apr;39(4):488-493. doi: 10.1097/MAO.0000000000001737.
A thorough literature search of the published English-language literature from 2011 to 2016 was performed in PubMed, Ovid, and Cochrane databases using the keywords ("Gamma Knife" or "CyberKnife" or "linear accelerator" or "radiosurgery") and ("glomus jugulare" or "jugular paraganglioma" or "glomus tympanicum").
Studies reporting outcomes of SRS for temporal bone GT were included.
Of 45 articles found, 15 studies met our inclusion and exclusion criteria and were selected for qualitative and quantitative analyses totaling 511 patients.
Average margin dose, modality, isodose line, volume decrease, follow-up duration, and tumor control rate data were extracted and analyzed.
Gamma Knife was the most commonly implemented radiosurgery modality and was used in eight studies. The mean marginal dose varied between 13.2 and 20 Gy. The pooled tumor control rate was 95.4% (95% CI: 93.6-97.2%) over a median follow-up duration ranging between 27.4 and 148 months. Clinical data on outcomes of SRS for the treatment of GTs are sparse and primarily limited to single institutional analyses, with considerable variation in tumor volume and follow-up duration. This meta-analysis provides an in-depth analysis of the available data in the literature and reviews the reported outcomes. Future studies on SRS for GT should include data on tumor growth before radiation as well as follow-up periods sufficiently long to identify true tumor control.
1)对立体定向放射外科(SRS)治疗颞骨球瘤(GT)的结果的现有数据进行荟萃分析,2)评估 SRS 治疗在肿瘤控制方面的综合结果。
在 PubMed、Ovid 和 Cochrane 数据库中,使用关键字(“伽玛刀”或“CyberKnife”或“线性加速器”或“放射外科”)和(“颈静脉球”或“颈静脉副神经节瘤”或“鼓室球瘤”)对 2011 年至 2016 年发表的英文文献进行了全面的文献检索。
纳入了报告 SRS 治疗颞骨 GT 结果的研究。
在发现的 45 篇文章中,有 15 项研究符合我们的纳入和排除标准,并选择了 511 名患者进行定性和定量分析。
提取并分析了平均边缘剂量、方式、等剂量线、体积减少、随访时间和肿瘤控制率数据。
伽玛刀是最常用的放射外科方式,在八项研究中使用。平均边缘剂量在 13.2 至 20 Gy 之间。在中位数随访时间为 27.4 至 148 个月之间,汇总的肿瘤控制率为 95.4%(95%置信区间:93.6-97.2%)。关于 SRS 治疗 GT 的结果的临床数据很少,主要限于单机构分析,肿瘤体积和随访时间差异很大。本荟萃分析对文献中的现有数据进行了深入分析,并回顾了报告的结果。未来关于 GT 的 SRS 研究应包括放射前肿瘤生长的数据以及足够长的随访时间以确定真正的肿瘤控制。